Skip to main content
. 2022 Jan 19;19(10):3511–3520. doi: 10.1021/acs.molpharmaceut.1c00841

Figure 5.

Figure 5

Biodistribution analysis of [111In]In-DTPA-B9 (4 h after injection), [111In]In-DTPA-B9-ABDlow (24 h post injection), and [111In]In-DTPA-B9-ABDhigh (72 h post injection) with or without injection of a molar excess girentuximab at 24 h before tracer injection.